Including women in clinical trials when there may be risk to them and their fetuses involves ethics challenges, and they can ...

Orforglipron significantly reduces body weight across all BMI categories in the ATTAIN-1 trial, with results presented at AACE 2026.

(HealthDay News) — Advanced cardiovascular-kidney-metabolic (CKM) syndrome stage, especially stages 3 and 4, is associated with increased cancer risk, according to a study published online April 27 in ...

Mitomycin gel has a favorable durability of response rate at 24 months among treated trial patients with low grade, intermediate-risk non-muscle invasive bladder cancer.

Baseline MMSE <24 linked to increased risk for kidney replacement therapy initiation, all-cause mortality, and MACE.

Phase 3 trial data show a synthetic semaglutide injection provides glycemic control comparable to Ozempic in patients with type 2 diabetes.

The NKF 2026 Spring Clinical Meetings will take place at the New Orleans Ernest N. Morial Convention Center in New Orleans, ...

Improvements in some domains of cognitive function seen for patients with cancer receiving chemotherapy reporting cognitive problems.

For adults with type 2 diabetes (T2D), a ketogenic diet (KD) reduces the proportion of proinsulin secreted to a greater extent than a low-fat diet (LFD), acco ...

Extreme weather may increase the risk of cardiovascular disease, according to a study published online April 21 in the American Journal of Preventive Medicine ...

Monoclonal antibodies clear amyloid plaques but only modestly preserve cognition for patients with early Alzheimer disease, MCI.

Increased cancer risks seen in association with each 1-µg/m3 increase in the 36-month moving-average of WFS fine particulate matter.